Following the suspension of the agreement, both the companies will retain their businesses and operate independently.
Merck and Sanofi-aventis are discontinuing their agreement primarily because of the increasing complexity of implementing the proposed transaction, both in terms of the nature and extent of the anticipated divestitures and the length of time necessary for the worldwide regulatory review process.
The suspension of the agreement is without penalty to either party and each party is responsible for its own expenses.